相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。An Antibody against the C-Terminal Domain of PCSK9 Lowers LDL Cholesterol Levels In Vivo
Felix Schiele et al.
JOURNAL OF MOLECULAR BIOLOGY (2014)
Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies
Nabil G. Seidah
CURRENT PHARMACEUTICAL DESIGN (2013)
Proprotein convertase subtilisin/kexin type 9 inhibition
David A. Marais et al.
CURRENT OPINION IN LIPIDOLOGY (2012)
Using Fragment-Based Technologies to Target Protein-Protein Interactions
Justin F. Bower et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Small-Molecule Inhibitors of Protein-Protein Interactions: How to Mimic a Protein Partner
David C. Fry
CURRENT PHARMACEUTICAL DESIGN (2012)
Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification
Kristian Tveten et al.
HUMAN MOLECULAR GENETICS (2012)
The M2 Module of the Cys-His-rich Domain (CHRD) of PCSK9 Protein Is Needed for the Extracellular Low-density Lipoprotein Receptor (LDLR) Degradation Pathway
Yascara Grisel Luna Saavedra et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Calcium-Independent Inhibition of PCSK9 by Affinity-Improved Variants of the LDL Receptor EGF(A) Domain
Yingnan Zhang et al.
JOURNAL OF MOLECULAR BIOLOGY (2012)
Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
James M. McKenney et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Phage Display-directed Discovery of LEDGF/p75 Binding Cyclic Peptide Inhibitors of HIV Replication
Belete A. Desimmie et al.
MOLECULAR THERAPY (2012)
The biology and therapeutic targeting of the proprotein convertases
Nabil G. Seidah et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation
Nabil G. Seidah et al.
PLOS ONE (2012)
Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor
Oystein L. Holla et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Role of ubiquitination in PCSK9-mediated low-density lipoprotein receptor degradation
Yanqun Chen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH
Paola Lo Surdo et al.
EMBO REPORTS (2011)
Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors
Oystein L. Holla et al.
JOURNAL OF LIPID RESEARCH (2011)
A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake
Yan G. Ni et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain
Mali Liu et al.
JOURNAL OF LIPID RESEARCH (2010)
The LDL Receptor
Joseph L. Goldstein et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
PCSK9 Impedes Hepatitis C Virus Infection In Vitro and Modulates Liver CD81 Expression
Patrick Labonte et al.
HEPATOLOGY (2009)
Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants
Matthew J. Bottomley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Genetic variants in PCSK9 in the Japanese population: Rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population
Yasuko Miyake et al.
ATHEROSCLEROSIS (2008)
Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment
Gilles Lambert et al.
CLINICAL CHEMISTRY (2008)
Proprotein convertase Subtilisin/Kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
Ahmed Zaid et al.
HEPATOLOGY (2008)
Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels
Gaetan Mayer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Functional analysis of sites within PCSK9 responsible for hypercholesterolemia
Shilpa Pandit et al.
JOURNAL OF LIPID RESEARCH (2008)
Molecular basis for LDL receptor recognition by PCSK9
Hyock Joo Kwon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The self-inhibited structure of full-length PCSK9 at 1.9 Å reveals structural homology with resistin within the C-terminal domain
Eric N. Hampton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Protein-protein interaction hotspots carved into sequences
Yanay Ofran et al.
PLOS COMPUTATIONAL BIOLOGY (2007)
The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol
Derek E. Piper et al.
STRUCTURE (2007)
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
David Cunningham et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2007)
Molecular biology of PCSK9: its role in LDL metabolism
Jay D. Horton et al.
TRENDS IN BIOCHEMICAL SCIENCES (2007)
New method for fast and accurate binding-site identification and analysis
Tom Halgren
CHEMICAL BIOLOGY & DRUG DESIGN (2007)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A spectrum of PCSK9 Alleles contributes to plasma levels of low-density lipoprotein cholesterol
IK Kotowski et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Druggability indices for protein targets derived from NMR-based screening data
PJ Hajduk et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia
TP Leren
CLINICAL GENETICS (2004)
Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream
MR Arkin et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype
KN Maxwell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes
JD Horton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):: Liver regeneration and neuronal differentiation
NG Seidah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice
KN Maxwell et al.
JOURNAL OF LIPID RESEARCH (2003)
On the role of the crystal environment in determining protein side-chain conformations
MP Jacobson et al.
JOURNAL OF MOLECULAR BIOLOGY (2002)
分享论文
